Free Alerts   Login
Health Care › Pharmaceutical Preparations

XERS Stock Price Correlated With Xeris Pharmaceuticals Financials

XERS Stock Price vs. Quarterly
XERS
Income Statement
Cash Flow
Balance Sheet

XERS Income Statement

Enable JavaScript and reload
Revenue, Net:
Revenue Per Share:
Cost of Goods & Services Sold:
Gross Profit:
Selling, General & Admin Expense:
Research & Development Expense:
Total Operating Expenses:
Operating Income:
Income Taxes:
Net Income:
Earnings Per Share, Diluted:
Earnings Per Share, Basic:
Shares Outstanding, Basic Avg:
Shares Outstanding, Diluted Avg:
Common Stock Shares Outstanding:

XERS Cash Flow

Enable JavaScript and reload
Operating Activities Net Income:
Depreciation, Depletion & Amortization:
Change in Accounts Receiveable:
Net Cash from Operations:
Net Cash from Operations Per Share:
Repurchases/Buybacks Common Stock:
Issuance of Long-term Debt:
Cash Dividends Paid:
Net Cash from Financing Activities:
Property, Plant & Equipment Purchases:
Purchases of Businesses, Net of Cash:
Net Cash from Investing Activities:
Net Change in Cash & Equivalents:

XERS Balance Sheet

Enable JavaScript and reload
Cash and Cash Equivalents:
Short-Term Investments:
Accounts Receivable, Net:
Inventories:
Total Current Assets:
Property, Plant & Equipment, Net:
Total Assets:
Accounts Payable:
Current Portion of Long-Term Debt:
Total Short-Term Liabilities:
Long Term Debt, Non-Current Portion:
Total Long-Term Liabilities:
Total Liabilities:

Major Holders (from 13F filings)

Investment Type
Change
Value (x$1000)
increase or decrease
Blackrock.
10,011,391 sh
637,149 sh
7%
$23,526
$6,089
Vanguard Group
7,086,345 sh
60,181 sh
1%
$16,653
$3,585
Stonepine Capital Management
5,937,000 sh
21,628 sh
0%
$13,952
$2,949
Caxton
5,641,920 sh
 
$13,259
Mpm Oncology Impact Management Lp
3,847,232 sh
-127,767 sh
-3%
$9,041
-$1,373
Geode Capital Management
2,892,077 sh
118,784 sh
4%
$6,797
$1,638
State Street
2,724,126 sh
154,004 sh
6%
$6,402
$1,622
Millennium Management
1,547,955 sh
-726,189 sh
-32%
$3,638
-$592
Renaissance Technologies
1,381,640 sh
359,600 sh
35%
$3
$1
Morgan Stanley
1,221,358 sh
583,126 sh
91%
$2,870
$1,683
Northernrp
1,165,363 sh
20,146 sh
2%
$2,738
$608
D. E. Shaw & Co..
1,054,610 sh
179,200 sh
20%
$2,478
$850
Redmile Group
1,046,587 sh
 
$2,459
Invenomic Capital Management Lp
568,619 sh
568,619 sh
NEW
$1,336
$1,336
Tudor Investment Et Al
553,411 sh
-88,087 sh
-14%
$1,301
$108
Ameriprise Financial
520,121 sh
-67,817 sh
-12%
$1,222
$128
Nuveen Asset Management
424,972 sh
-287,725 sh
-40%
$999
-$327
Gsa Capital Partners
416,267 sh
35,036 sh
9%
$978
$269
Lazard Asset Management
403,813 sh
88,326 sh
28%
$1
Citadel Advisors
400,577 sh
360,277 sh
894%
$942
$867

Free historical financial statements for Xeris Pharmaceuticals Inc. See how revenue, income, cash flow, and balance sheet financials have changed over 10 quarters since 2019. Compare with XERS stock chart to see long term trends.

Data imported from Xeris Pharmaceuticals Inc SEC filings. Check original filings before making any investment decision.